Tenofovir alafenamide
Tenofovir alafenamide has been studied in 12 papers since 2022: 2 trials and 3 observational studies in people, 2 in animals, 2 in cells, 3 reviews; 7 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Longitudinal changes in the odds of metabolic syndrome among people living with HIV receiving dolutegravir-, tenofovir alafenamide-, or…”.
1 new paper in 30 daysSee all 15 papers on tenofovir alafenamide
At a glance
The findings reach people, from one lab or study. 5 independent labs in 4 countries; 88 trials, none about aging, 20 with no results posted.
“We demonstrated a trend to increased BMD at the lumbar spine after a switch from TDF to TAF in peri- and early postmenopausal women living with HIV.”
None of its findings points the other way.
- 5 independent labs in 4 countries
- 88 trials, none about aging, 20 with no results posted
- Funder: Korean Association for the Study of the Liver
- Human trial2
- Humans3
- Animals2
- Cells2
Studies in people
1 study gave tenofovir alafenamide to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases bone mineral density1.97% (-1.15 to 5.49) vs -2.32% (-5.11 to 0.19) | Randomized trial48 weeks | 34 peopleWomenmedian 51 yearsMidlife adults; Postmenopausal women; peri- and early postmenopausal women living with HIV | AIDS research and human retroviruses, Dec 14, 2022 |
What did studies of tenofovir alafenamide find?
4Studies of tenofovir alafenamide measured 4 outcomes, among them MYOD1, cellular senescence and bone mineral density.
MYOD1
downin human cells1
1 study
MYOD1
downin human cells1
Tenofovir alafenamide decreases MYOD1 in primary human mesenchymal stem cells and myoblasts.
“Moreover, FTC and TAF decreased expression of myoblast differentiation markers (MYOG and MYOD).”
Cellsin primary human mesenchymal stem cells and myoblasts
THE AHR AS A POTENTIAL MEDIATOR OF MUSCULOSKELETAL FRAILTY WITH ANTI-RETROVIRAL THERAPY
GSA 2024 abstract
Cellular senescence
upin human cells1
1 study
Cellular senescence
upin human cells1
Tenofovir alafenamide increases cellular senescence in primary human mesenchymal stem cells and myoblasts.
“showing increased expression of AhR, AhR target genes, and increased senescence in both cell populations.”
Cellsin primary human mesenchymal stem cells and myoblasts
THE AHR AS A POTENTIAL MEDIATOR OF MUSCULOSKELETAL FRAILTY WITH ANTI-RETROVIRAL THERAPY
GSA 2024 abstract
Bone mineral density
upin humans1
1 study
Bone mineral density
upin humans1
Tenofovir alafenamide increases bone mineral density in humans (peri- and early postmenopausal women living with HIV) (1.97% (-1.15 to 5.49) vs -2.32% (-5.11 to 0.19)).
“We demonstrated a trend to increased BMD at the lumbar spine after a switch from TDF to TAF in peri- and early postmenopausal women living with HIV.”
Human trialperi- and early postmenopausal women living with HIVlumbar spine48 weeksfemalesn = 34
AIDS research and human retroviruses
Skeletal muscle mass
upin humans1
1 study
Skeletal muscle mass
upin humans1
Tenofovir alafenamide is linked with higher skeletal muscle mass in humans (people living with HIV).
“The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group.”
Humanspeople living with HIVmalesn = 87
Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
Medicine
What is tenofovir alafenamide linked with?
2Studies link tenofovir alafenamide with 2 measures: atherosclerotic cardiovascular disease and osteoporotic fractures.
Atherosclerotic cardiovascular disease
downin humans1HR 0.7
1 study
Atherosclerotic cardiovascular disease
downin humans1HR 0.7
Tenofovir alafenamide is linked with a lower risk of atherosclerotic cardiovascular disease in humans after PS matching (HR 0.70, p < 0.001).
“TAF was associated with lower ASCVD risk than TDF (4.60 vs. 6.88/1000 PYs; p < 0.001), a trend maintained after PS matching (4.67 vs. 6.67/1000 PYs; hazard ratio 0.70; p < 0.001)”
Humansafter PS matching
Journal of medical virology
Osteoporotic fractures
downin humans1HR 0.68
1 study
Osteoporotic fractures
downin humans1HR 0.68
Tenofovir alafenamide is associated with osteoporotic fractures in humans (HR 0.68, 95% CI 0.55–0.85; 0.49 versus 0.78 fractures per 100 person-years).
“TAF-treated patients with CHB had a significantly lower risk of osteoporotic fracture than TDF-treated patients.”
HumansChronic hepatitis B; compared with tenofovir disoproxil fumarate, after inverse probability treatment weighting24.4 ± 11.6 months64.5% mensn = 32,582
Alimentary pharmacology & therapeutics
Has tenofovir alafenamide been tested in people?
0 of 88 about agingYes: 2 trials and 3 observational studies in people have been published, and 88 trials are registered.
Approved
Nov 10, 2016Hepatitis B Virus, Hepatitis B, Chronic, Hepatitis B Virus Infection, chronic hepatitis B virus infection
Jan 9, 2017Hepatitis B, Chronic Hepatitis B in Adults and Paediatric Patients
Repurposing
Phase 4Status unknown1 trial
Phase 4Completed9 trials
Phase 4Recruiting1 trial
Phase 4Status unknown1 trial
Phase 4Status unknown1 trial
Phase 4Results posted1 trial
All 22Fewer
In trials
Hbv
Phase 4Status unknown3 trials
HIV Prevention
Phase 4Completed2 trials
Human immunodeficiency virus i infection
Phase 4Status unknown1 trial
Lentivirus infection
Phase 4Recruiting1 trial
B-cell leukemia
Phase 2Terminated1 trial
Chronic hepatitis D
Phase 2Results posted1 trial
All 10Fewer
Readouts due
- Jan 2027
Phase 4Active, not recruiting
- Jun 17, 2027
Stopped
NCT03804372TerminatedB-cell leukemia
low enrollment rate
Who is developing tenofovir alafenamide?
3 companies: Merck Sharp & Dohme, Humanis Saglık Anonim Sirketi and Janssen Research & Development.
Trial sponsors
Company1 trialPhase 4100 people
Company1 trialPhase 475 people
Company3 trialsPhase 3700 people
Chia Tai Tianqing Pharmaceutical Group
Company1 trialPhase 3930 people
Janssen Research & Development
Company7 trialsPhase 2312 people
Company1 trialPhase 265 people
Company1 trialPhase 25 people
Company1 trialPhase 172 people